<h4>Introduction</h4>Histone deacetylase 6 (HDAC6) inhibitors have shown effectiveness in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN), a severe side effect of various antineoplastic drugs, with no available preventive or therapeutic treatments. This evidence concerns the gene HDAC6 and peripheral neuropathy.